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Abstract
Objective: We conducted a prospective cohort study of the Clinical Practice Research Database to 
estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative 
effects on smoking cessation, and mental health.
Methods: We used multivariable logistic regression, propensity score matched regression, and 
instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders 
were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, 
antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and in-
cidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. 
Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years.
Results: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-
eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were pre-
scribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 
2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% 
(95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% 
(95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to 
NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health 
outcomes than NRT in patients both with and without mental disorders, although there was some 
variation when analyses were stratified by mental disorder subgroup.
Conclusions: Smoking cessation medication prescribing may be declining in primary care. 
Varenicline was more effective than NRT for smoking cessation in patients with mental disorders 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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and there is not clear consistent evidence that varenicline is adversely associated with poorer 
mental health outcomes.
Implications: Patients with mental disorders were less likely to be prescribed varenicline than 
NRT. We triangulated results from three analytical techniques. We found that varenicline was more 
effective than NRT for smoking cessation in patients with mental disorders. Varenicline was gen-
erally associated with similar or decreased odds of poorer mental health outcomes (ie, improve-
ments in mental health) when compared with NRT. We report these findings cautiously as our data 
are observational and are at risk of confounding.
Background
Smoking is the world’s leading cause of preventable illness and death.1 
One in every two smokers will die because of their addiction unless 
they quit.2 In many countries, such as the United Kingdom, smoking 
prevalence has decreased from 46% during 1970s to about 16% in 
recent years.3 However, smoking prevalence has not changed to the 
same extent in people with mental disorders. Smoking prevalence in 
people with mental disorders was estimated at around twice the rate 
of the general population at 40% in 2010/2011.4 People with mental 
disorders smoke more cigarettes per day, are more heavily addicted, 
and are more likely to relapse than are the general population.5 The 
burden of smoking-related mortality and morbidity in people with 
mental disorders is clear, with estimates of lowered life expectancy of 
up to 18 years when compared with the general population.6
Data from Cochrane Group meta-analyses of randomized con-
trolled trials (RCTs),7 and from recent observational studies have 
found that varenicline produces higher quit rates compared with 
nicotine replacement therapy (NRT) in the general population.8 
However, there has been controversy around the neuropsychiatric 
safety of this drug and therefore clinicians may be reluctant to pre-
scribe varenicline to smokers with mental disorders. However, ob-
servational studies and RCTs show little evidence that varenicline 
increases risks of neuropsychiatric harms in the general population.7,9
There are few studies examining the effectiveness of varenicline 
and varenicline’s association with mental health outcomes in people 
with mental disorders. Molero et  al.10 reported an association be-
tween varenicline and increased risk of mood and anxiety conditions 
in people with psychiatric conditions, hazard ratio for anxiety con-
ditions, 1.23 (95% CI: 1.01% to 1.51%) and mood conditions, 1.31 
(95% CI: 1.06% to 1.63%), however they did not stratify analyses 
by mental disorder (eg, schizophrenia). The EAGLES RCT compared 
NRT and varenicline for smoking cessation and neuropsychiatric 
safety in a psychiatric cohort,11 and reported that varenicline pro-
duced higher abstinence rates compared with NRT at 9- to 24-weeks 
follow-up, odds ratio 1.51 (95% CI: 1.19% to 1.93%), and found 
little evidence that varenicline caused neuropsychiatric harm 
when compared to NRT, risk difference 1.22 (95% CI: −0.81% to 
3.25%).11 However, the trial’s longest follow-up was 24 weeks and 
was underpowered to detect rare events, particularly when stratified 
by mental diagnosis.
Therefore, in this study in the Clinical Practice Research Database 
(CPRD) we aimed to:
 1. Describe rates of smoking cessation medication prescribing, and 
smoking prevalence stratified by mental disorder in primary care 
from 2006 to 2015.
 2. Estimate the relative effectiveness of varenicline and NRT on 
smoking cessation in patients with mental disorders, compared 
with those without mental disorders, at 3, 6, 9 months and 1, 2, 
4 years after first prescription.
 3. Determine the association between varenicline or NRT and sub-
sequent diagnosis of depression, neurotic disorder, prescription 
of anti-depressants, or hypnotics/anxiolytics in patients with 
mental disorders, compared with those without mental dis-
orders, at 3, 6, 9 months and 1, 2, 4 years after first prescription.
Because we were concerned about confounding we triangulated 
results across three different analytical methods12: multivariable 
logistic regression, propensity score matched regression, and instru-
mental variable analysis.
Methods
We conducted a prospective cohort study using electronic medical 
records from 654 general practices in England from 2006 onwards.13 
It was approved by the Independent Scientific Advisory Committee 
for MHRA Database Research (www.cprd.com/isac/).
Data Source and Population
We obtained data from the Clinical Practice Research Database 
(CPRD) (www.cprd.com) which contains data on more than 13 mil-
lion UK primary care patients. Registered patients are representative 
of the United Kingdom’s population.14 CPRD data have been valid-
ated, audited, and quality checked.15
Code Lists
We defined variables using medical and product codes within the 
CPRD. Code lists were developing using a  list from a previously 
published study16 and then agreed upon by field experts (DR and 
KHT), and by using the British National Formulary (BNF) and the 
International Classification of Diseases (ICD-10).
Patients
We included smokers and nonsmokers for smoking prevalence es-
timates, and we included smokers prescribed either varenicline or 
NRT for effectiveness/safety estimates. For all aims, we included 
patients aged ≥18 years, with no breaks in their electronic medical 
records, who had complete information on year of birth, registra-
tion date, and sex. For the effectiveness/safety analysis, we excluded 
patients who registered with their general practice within 365 days 
of their first recorded varenicline/NRT prescription to ensure avail-
ability of baseline and exposure data.
Patients were categorized as having a mental disorder if: (1) 
they had been diagnosed with one of the following common mental 
disorders 365  days before first varenicline/NRT prescription: 
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depression (F32–F39), neurotic disorder (F40–F48), (2) if they had 
a lifetime record of bipolar disorder (F30–F31), or schizophrenia 
or other nonaffective psychotic disorders (F20–F29), or (3) if they 
were prescribed any of the following medications 365 days before 
smoking cessation medication prescription: antidepressants (BNF 
chapter 4.3), antipsychotics (4.2.1.–4.2.2), hypnotics or anxiolytics 
(4.1), or mood stabilizers (4.2.3). Patients with no record of the 
above listed mental disorders or psychoactive medication prescrip-
tions were considered to have no mental disorder.
Variables
Defining Variables for Prevalence of Smoking, and NRT and 
Varenicline Prescribing Estimates
For smoking prevalence estimates a patient’s smoking status (aged 
≥18 years) was defined by a record indicating smoking/nonsmoking 
or prescription of NRT/varenicline in that year, and restricted to 
within the registration date for each patient. Each patient’s smoking 
status was carried forward until there was evidence of a change in 
smoking status or carried backward if the patient only had smoking 
status recorded in the final year of their registration period.
Prevalence of prescriptions of varenicline and NRT were calcu-
lated by dividing the number of prescriptions each year from 2007 to 
2015 (there were very few varenicline prescriptions for patients with 
mental disorders in 2006) by the number of current smokers in each 
year. In both instances, prevalence was estimated for people with and 
without mental disorders.
For both smoking and prescribing prevalence, we generated 
standardised rates (with 95% CIs) using a direct standardisation 
method to account for differences in age (ie, 18–24, 25–34, 35–49, 
50–59, 60+ years) and sex between groups. We used the CPRD 
population in 2015 as our standard population for calculating 
standardised smoking rates, and the CPRD smoker population 
in 2015 as our standard population for calculating standardised 
prescribing prevalence rates. Individuals with missing smoking 
information were excluded from the denominators.
Intervention Groups
The intervention was defined as varenicline prescription, and con-
trol as NRT prescription (eg, patches, etc.). Prescriptions used to 
define treatment groups were issued between September 1, 2006 and 
August 31, 2016, with no prior record of use of a related product in 
the preceding 18 months. We used the first treatment episode to en-
sure that intervention groups were “new users” of the medication.17 
We did not model treatment switching because this is likely to be 
strongly related to patient characteristics and the resulting pattern 
of time-dependent confounding-by-indication would be difficult to 
control for. Intervention was defined using a variable representing 
NRT (0) or varenicline (1).
Outcomes
Smoking Cessation. This was defined as having an electronic record 
indicating smoking cessation.18 From April 1, 2004 general practi-
tioners (GPs) have been incentivised to opportunistically record pa-
tients’ smoking status as current, former or never smoker in their 
records; these data are repeatedly recorded (ie, at registration and 
on a regular basis thereafter)19 as part of a nationwide incentive 
program20 and these smoking records are consistent with smoking 
prevalence reported in representative population surveys.21 We 
determined each patient’s smoking status by using their most recent 
smoking record identified between cohort entry and each follow-up 
period (eg, 3 and 6 months); that is, the closest smoking record to 
each follow-up period was selected. For analyses smoking status was 
defined as smoker (0) or quit (1). Patients with missing smoking data 
were assumed to be continuing smokers.22 This definition has been 
used previously and is robust to sensitivity tests in which we multiple 
imputed missing outcome data.23
Mental Health Safety. Safety outcomes were defined as any newly 
occurring medical record indicating depression, neurotic disorder, 
or prescription of antidepressants, hypnotics/anxiolytics after pre-
scription of smoking cessation medication. Records were analysed as 
present (1) or absent (0). In analyses where diagnosis of depression 
or neurotic disorder were the outcomes, we excluded patients with 
the diagnoses 365 days before exposure (ie, where depression was 
the outcome, patients with depression diagnosis 365 days before ex-
posure were excluded). We did this because change in diagnoses are 
unlikely to be consistently recorded in the CPRD.
Covariates
Covariates included patients’ age at time of prescription, sex, year of 
prescription, days registered in the CPRD, history of mental disorder 
or psychoactive medication prescriptions, evidence of other psycho-
active medication prescription or other less common psychiatric 
disorders (Supplementary Material 1 for details), drug or alcohol 
misuse, mean number of GP visits one year prior to first prescrip-
tion, body mass index (BMI), socioeconomic position (ie, index of 
multiple deprivation [IMD]) and the Charlson Index (ie, measure of 
chronic illness).24
Follow-up
Primary follow-up was 2-years after each patient’s first prescription 
of varenicline or NRT. Patients were also followed-up at 3, 6, and 
9 months and 1 and 4 years after first prescription of varenicline or 
NRT.
Statistical Analysis
Analyses were conducted using Stata 14 MP. Analytic code is available 
on GitHub (https://github.com/nmdavies/varenicline-mentalhealth).
Smoking and Smoking Cessation Medication Prescribing 
Prevalence Overtime
Formulae described in Supplementary Material 1 were used to cal-
culate smoking and prescribing prevalence each year from 2007, in 
patients with and without mental disorders.
Varenicline’s Effectiveness for Smoking Cessation Compared 
with NRT
To investigate the effectiveness of varenicline versus NRT on 
smoking cessation we conducted: (1) multivariable logistic regres-
sions, (2) propensity score matched logistic regressions, and (3) 
instrumental variable regressions using physicians’ prescribing pref-
erences as the instrument.25
All regression models were estimated using robust standard 
errors, which allowed for potential clustering of patients within 
practices. Models were repeated in patients: with no mental dis-
order, any mental disorder; bipolar, depression, neurotic disorder, or 
schizophrenia; prescribed any psychoactive medication; prescribed 
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antidepressants, antipsychotics, hypnotics/anxiolytics, or mood 
stabilizers.
We used Bland–Altman tests to determine if the effectiveness 
of varenicline differed at 2-years follow-up between patients with 
or without mental disorders (Supplementary Material 1 for further 
details).
Multivariable adjusted results can suffer from residual con-
founding by indication (ie, patients prescribed varenicline might be 
healthier at baseline than those prescribed NRT).26 We addressed 
this by repeating all analyses using: propensity score matched re-
gression by matching patients on the association between their ex-
posure and baseline characteristics (ie, days of history, sex, age at 
time of first prescription, BMI, multiple deprivation score, number 
of GP visits 1 year before first prescription, year of first prescrip-
tion, comorbidity ever (Charlson Index), alcohol misuse ever, drug 
misuse ever, bipolar ever, depression ever, neurotic disorder ever, 
schizophrenia ever, anti-depressants ever, antipsychotics ever, hyp-
notics ever, mood stabilizers ever, prescription of rare psychotropic 
medication ever, diagnosis of other mental disorder ever), and in-
strumental variable regression models using physicians’ prescribing 
preferences as the instrument.25 Instrumental variables are proxies 
for the exposure and defined by the following characteristics: they 
are related to the intervention, their association with the outcome 
has no confounders, and they do not directly affect the outcome 
except via the intervention.27 Physicians’ prescribing preferences for 
varenicline or NRT have been shown to be suitable instrumental 
variables.23 We used a physician’s prescription to their previous 
patient as a proxy for their prescribing preference.25,27 If the in-
strumental variable assumptions hold, and multivariable adjusted 
regression results suffer from residual confounding, then the results 
will differ. However, instrumental variable methods require large 
sample sizes, as they have lower power than standard regression 
models because the instrument only explains some of the variance 
in prescribed treatment. See Supplementary Material 1 for details of 
analytical methods.
Varenicline’s Mental Health Safety Compared With NRT
To determine the mental health safety of varenicline relative to NRT 
we repeated the analyses described above, with the following out-
comes: diagnosis of depression or neurotic disorder, prescription of 
antidepressants or hypnotics/anxiolytics (ie, as defined above).
Missing Data
To increase efficiency and minimize selection bias, we used mul-
tiple imputation to impute data in patients missing BMI and IMD 
values.28 Using the ICE command, we produced 20 imputed datasets, 
and the imputation model included all exposures, covariates, and 
outcomes.28
Results
Smoking and Smoking Cessation Medication 
Prescribing Prevalence Overtime
The age and sex standardised smoking prevalence among people 
with any mental disorder diagnosis/psychoactive medication pre-
scription consistently decreased from 38.6% and 36.6% in 2006 to 
32.0% and 29.9% in 2015 (respectively). These estimates were con-
sistently higher than in people with no mental health diagnosis or 
prescription (from 14.5% in 2006 to 10.9% in 2015; Supplementary 
Material 1, eFigure 1). Between 2006 and 2015, smoking prevalence 
decreased in all mental disorders and similarly in patients who were 
prescribed any of the psychoactive medications (Supplementary 
Material 1, eFigure 2).
Standardised NRT prescribing rates fell between 2007 and 2015 
in smokers with and without mental disorders. Varenicline pre-
scribing increased between 2007 and 2011 and then fell between 
2011 and 2015 in smokers with and without mental disorders. From 
2010 to 2015, both NRT and varenicline prescribing was higher 
among smokers with mental disorders as compared with those 
without (Figure 1).
Varenicline’s Effectiveness and Mental Health Safety 
Compared With NRT
Population Characteristics
There were 361,656 patients prescribed smoking cessation medica-
tions between September 1, 2006 and August 31, 2016. Of these 
235,314 were eligible for analysis, 159,736 smokers were pre-
scribed NRT and 75,578 prescribed varenicline. Supplementary 
Material 1, eFigure 3 presents the number of patients excluded with 
reasons.18 Of those prescribed NRT, a range of products were is-
sued: (Supplementary Material 1, eTable 5); 37,009 (23.1%) of the 
patients prescribed NRT were prescribed more than one type of 
product. At the time of smoking cessation medicine prescription, the 
mean age of the participants was 45.8 years (SD = 14.9) and 54% 
of the cohort were women (Table 1). Baseline data indicated that 
this cohort was similar to other studies of smokers from the United 
Kingdom.4,16,29
Effectiveness
In the cohort, smokers with mental disorders had 31% (95% 
CI: 29% to 33%) decreased odds of being prescribed varenicline 
than NRT, compared with smokers without mental disorders 
(Supplementary Material 1, eTables 3–4). A higher proportion of 
patients prescribed varenicline had quit smoking at all follow-ups, 
compared to those prescribed NRT (Figure 2). At 2 years, smokers 
with mental disorders prescribed varenicline had 19% (95% CI: 
15% to 24%) higher odds of quitting smoking (fully adjusted odds 
ratio) than those prescribed NRT (Figure 3, Supplementary Material 
1, eTables 6–8); the association was smaller in patients with mental 
disorders than in those without mental disorders at 2 years (Bland–
Altman p value = .02, Supplementary Material 1, eTable 9). The as-
sociation between varenicline and smoking cessation persisted from 
3 months to 4 years but attenuated over time in all patients.
Smokers prescribed varenicline had higher odds of quitting at 
2  years for all mental disorder subgroups than those prescribed 
NRT. However, estimates in patients with bipolar disorder were im-
precise (ie, wide confidence intervals). When compared with patients 
without mental disorders, there was some evidence that the odds of 
2-year smoking cessation in those prescribed varenicline compared 
with NRT was smaller in those prescribed antidepressants (Bland–
Altman p value = .01, Supplementary Material 1, eTable 9). There 
was little evidence of heterogeneity for the effectiveness estimates 
between the other mental disorder groups and patients without 
mental disorders (all Bland–Altman p > .05, Supplementary Material 
1, eTable 9). At all other follow-ups, patients prescribed varenicline 
were more likely to quit compared with NRT (Supplementary 
Material 1, eTables 7 and 8), although estimates in bipolar and 
schizophrenia patients were imprecise.
The propensity score matched regression models produced similar 
results to the multivariable logistic regression models (Supplementary 
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Material 1, eTable 10). The instrumental variable models indicated 
that smokers with any mental disorder prescribed varenicline were 
more likely to quit smoking at 2 years, than those prescribed NRT; 
the risk difference per 100 patients treated was 4.91 (95% CI: 2.42% 
to 7.40%); this association persisted up to 4  years (Supplementary 
Material 1, eTables 11 and 12). However, models were imprecise for 
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Figure 1. Age and sex standardised percentage (%) of prescriptions of varenicline or NRT in primary care, from 2007 to 2015, in smokers with any mental 
disorder, compared with smokers with no mental disorder.
Table 1. Baseline Characteristics by Intervention Group, N (%)
Characteristic Whole cohort (N = 235 314) NRT (N = 159 736) Varenicline (N = 75 578)
Age at time of first prescriptiona 45.8 (14.9) 46.3 (15.6) 44.4 (13.2)
Sex (female) 116 581 (52.6%) 85 876 (53.8%) 37 883 (50.1%)
Multiple deprivation score (IMD)b,c 12 12 12
Number of GP visits 1 year before first prescriptiona 6.9 (7·1) 7·9 (7·4) 6·3 (6·1)
BMIb,c 26.5 (0.01) 26.5 (0.02) 26.5 (0.02)
Year of first prescriptiond 2009 2009 2010
Days of historya 3089.8 (1934.2) 3054.3 (1908.0) 3164.9 (1986.4)
Comorbidity ever (Charlson Index) 83 888 (35.7%) 59 843 (37.5%) 24 045 (31.8%)
Alcohol misuse ever 18 764 (8.0%) 13 994 (8.8%) 4770 (6.3%)
Drug misuse ever 6431 (2.7%) 4975 (3.1%) 1456 (1.9%)
Self-harm ever 23 960 (10.2%) 17 299 (10.8%) 6661 (8.8%)
Other psychoactive medication ever 640 (<1%) 513 (<1%) 127 (<1%)
Other behavioral/neurologic disorder ever 12 084 (5.1%) 9092 (5.7%) 2992 (4.0%)
Mental disorder diagnosis/prescription
 Any mental disorder diagnosis or psychoactive 
medication prescription
78 457 (33.3%) 59 340 (37.2%) 19 117 (25.3%)
 Bipolar disorder 2012 (<1%) 1799 (1.1%) 213 (<1%)
 Depression 17 168 (7.3%) 13 421 (8.4%) 3747 (5.0%)
 Neurotic disorder 8394 (3.6%) 6453 (4.0%) 1941 (2.6%)
 Schizophrenia and nonaffective psychoses 4704 (2.0%) 4263 (3.7%) 441 (<1%)
 Antidepressants 56 756 (24.1%) 43 589 (27.3%) 13 167 (17.4%)
 Antipsychotics 11 829 (5.0%) 9843 (6.2%) 1986 (2.6%)
 Hypnotics/anxiolytics 31 291 (13.3%) 23 651 (14.8%) 7640 (10.1%)
 Mood stabilizers 4728 (2.0%) 4079 (2.6%) 649 (<1%)
aData presented are mean and standard deviation.
bData presented are mean and standard error.
cMissing data: BMI data were missing for 14.1% (N = 33 059); IMD data were missing for 46.7% (N = 109 994), nonimputed data are presented. Missing BMI 
and IMD values were imputed using multiple imputation.29 See Supplement 1 for imputed data (Supplementary Material 1, eTable 2).
dData presented are median.
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most subgroups (Supplementary Material 1, eTable 12). There was 
little evidence of heterogeneity across most mental disorder subgroups 
(all Bland–Altman p > .05, Supplementary Material 1, eTable 13).
Mental Health Safety
At 2  years, patients with any or no mental disorder prescribed 
varenicline had similar or decreased odds of receiving diagnoses of 
depression, neurotic disorder, or prescriptions for anti-depressants 
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Figure 3. Stratified by mental disorder: The association of prescribing varenicline compared with NRT and smoking cessation at 2-years follow-up. Fully adjusted 
odds ratios and 95% confidence intervals from logistic regression models. Fully adjusted models were adjusted for: age, sex, days in history, IMD, number of GP 
visits 1-year before first prescription, BMI, year of first prescription, history of major physical morbidity (Charlson Index), alcohol misuse ever, drug misuse ever, 
bipolar ever, depression ever, neurotic disorder ever, self-harm ever, other mental disorder ever, antidepressant prescription ever, antipsychotic prescription 
ever, hypnotics/anxiolytics prescription ever, other psychoactive medication ever, other behavioral/neurologic disorder ever. Missing BMI and IMD values 
were imputed using multiple imputation.24 No mental disorder diagnosis or psychoactive medication prescription (N = 156 857); any mental disorder diagnosis 
or psychoactive medication prescription (N = 78 457); bipolar (N = 2011); depression (N = 17 168); neurotic disorder (N = 8394); schizophrenia (N = 8,394); 
antidepressants (N = 56 756); antipsychotics (N = 11 829); hypnotics/anxiolytics (N = 31 291); mood stabilizers (N = 4727).
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Figure 2. Percentage (%) of patients with an electronic medical record indicating smoking cessation at 2-years follow-up, by exposure and mental disorder.
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or hypnotic/anxiolytics than those prescribed NRT (Figure 4). 
These findings were consistent at all follow-ups and across all three 
analytical approaches (Supplementary Material 2, eTables 1–24). 
There was weak evidence that in patients with any mental disorder 
varenicline was associated with a small increase in depression diag-
nosis compared with NRT at 4 years and this was consistent across 
propensity score matched and instrumental variable models. There 
was evidence that patients with schizophrenia or those prescribed 
mood stabilizers who were prescribed varenicline were more 
likely to be diagnosed with depression than those prescribed NRT 
(Supplementary Material 2, eTables 5, 9 and 17); estimates from 
propensity score matching and instrumental variable analysis were 
in the same direction in these groups but were imprecise.
Discussion
Main Findings
Smoking prevalence was higher in patients with mental disorders, 
than in those without, and prescriptions of smoking cessation medi-
cations fell during the study period. Although varenicline was more 
effective than NRT for long-term smoking cessation in patients with 
mental disorders, general practitioners were less likely to prescribe 
varenicline than NRT to patients with mental disorders compared 
to those without. There was little evidence consistent evidence that 
varenicline was associated with greater odds of depression, neurotic 
disorder, antidepressant, or hypnotic/anxiolytic prescription in pa-
tients with or without a mental health disorder. Our findings were 
broadly consistent across multivariable regression and propensity 
score matched models. However, the instrumental variable models 
were underpowered to detect treatment effect heterogeneity for most 
mental disorder subgroups, as the instrument only explains some of 
the variance in prescribed treatment.
Strengths and Limitations
Data from the CPRD are representative of the UK population30 and 
other nations.31 Patients and clinicians were blinded to the study 
aims and therefore recall and reporting bias is unlikely to have in-
fluenced the results.
Exposure was routinely  recorded in primary care,30 thus, un-
likely to cause bias. The outcome, smoking status, is well reported 
in primary care,32 and was defined using expert-reviewed definitions, 
although it is unlikely that all patients had their smoking status con-
sistently recorded. Analyses from our previous work showed that 
misclassification bias (ie, classing quitters as continuing smokers, 
vice versa) is unlikely to bias estimates of the effect of prescribing 
varenicline on cessation.33 Mental health diagnosis outcomes are less 
consistently recorded in the CPRD, however prescriptions of anti-
depressants and hypnotics/anxiolytics are routinely recorded. Where 
covariate data were missing we used multivariable multiple imput-
ation to minimize selection bias.28
A strength of this study was the use of three different analyt-
ical methods to estimate the effectiveness and safety of varenicline.34 
The propensity score analysis produced very similar findings to the 
multivariable regression. Both of these analyses are likely to be af-
fected by residual confounding by unmeasured factors. For example, 
we are unable to account for tobacco addiction related characteris-
tics (eg, nicotine dependence) which may affect both type of smoking 
cessation medication prescribed and likelihood of quitting smoking.
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Figure 4. Fully adjusted odds ratio and 95% confidence intervals from logistic regression models for the association between varenicline compared with NRT 
with depression, neurotic disorder, and prescription of antidepressants or hypnotic/anxiolytics at 2 years, in patients with or without any mental disorder.
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Our instrumental variable analyses used naturally occurring 
variation in the GPs’ prescribing to mimic randomisation to min-
imize bias due to patient characteristics. The instrumental variable 
estimates suggested that patients with mental disorders who were 
prescribed varenicline were more likely to have quit at 2 years. For 
every 100 smokers treated with varenicline about seven additional 
smokers would quit as compared to 100 smokers treated with 
NRT, and this association persisted up to 4  years. However, the 
estimates from the instrumental variable analyses were imprecise 
to examine some associations when stratified by mental disorder 
(ie, IV methods require large sample sizes, as IV regressions are less 
powered than a standard regression model because the instrument 
only explains some of the variance in prescribed treatment). In add-
ition, while our previous work has shown that use of prescribing 
preferences is likely to be less affected by confounding than actual 
prescriptions received23,35 it is possible that clustering of patients 
with similar characteristics within GP surgeries may influence pre-
scribing preferences.
We had no information on whether patients adhered to their 
smoking cessation medication treatment. Evidence from studies of 
similar databases show that rates of smoking cessation medication 
prescribing in primary care are comparable to national dispensing 
rates.32 Other studies have found that users of NRT continue taking 
the medication less than half the time it is prescribed. In our data, 
there is no information about when or if patients took medicines 
they were prescribed. This means that we estimated the effect of 
prescribing smoking cessation medications allowing for real-world 
treatment adherence.
Comparison with Other Studies
Our smoking prevalence estimates are comparable to studies using 
similar databases for patients with mental disorders up to 2011,4,16,36 
and to studies of smoking prevalence in the general population up 
to 2015.3 Varenicline and NRT prescribing rates in smokers with 
and without mental disorders are comparable to those reported in 
the THIN database,4,16 and the decreasing trend is similar to that 
reported by a UK database of National Health Service prescribing 
records (https://openprescribing.net). There have been substan-
tial changes in the United Kingdom health care system over recent 
years, and considerable pressure on funding. One possibility is that 
these declines are a result of funding pressures. However, we cannot 
say with certainty solely based on prescribing data. Interestingly, 
despite this fall in prescribing rates, smoking in the population has 
declined considerably. Another potential explanation is the rising 
popularity of e-cigarettes in the United Kingdom may have re-
duced smoking treatment consulting.37 It is possible that patients 
are using e-cigarettes rather than varenicline and NRT. However, 
we cannot assess this possibility because our data contain no in-
formation on e-cigarette use. This would be an interesting topic for 
future research.
The EAGLES RCT compared the effect of varenicline versus 
NRT on smoking cessation in patients with mental disorders at 
9- to 24-weeks follow-up.11 The trial included patients with mood 
disorders, neurotic disorders, psychotic disorders, and personality 
disorders (N = 4116). They found that varenicline produced higher 
quit rates than NRT. The effect estimate reported in EAGLES was 
similar to the estimate derived from our study in patients with 
mental disorders at 6-months follow-up, and the estimates from our 
study are more precise.
Our study is the largest to date to examine the effects of 
varenicline on mental health outcomes, stratified by mental disorder. 
Our finding that varenicline is associated with better or similar 
mental health outcomes than NRT similar to findings from a meta-
analyses of observational studies in the general population and in 
those with depression.38 In our study, we found some weak evidence 
of an association between varenicline and greater odds of depres-
sion in people with schizophrenia and in patients prescribed mood 
stabilizers. Although this is the largest study to investigate this as-
sociation specifically in these mental health subgroups, these find-
ings are not consistent with the EAGLES trial.11 Our findings are 
in line with Molero et  al.’s study that reported an association be-
tween varenicline and greater odds of mood conditions in people 
with psychiatric conditions,10 however they did not stratify analyses 
by mental disorder. We report our findings cautiously as our data 
are observational and are at risk of confounding. In addition, we 
did not observe the same pattern of results in these subgroups for 
prescription of antidepressants, which are likely to be recorded more 
accurately than diagnoses. Furthermore, results from our IV analyses 
were imprecise in patients with schizophrenia.
Conclusions and Implications
Patients with mental disorders were less likely to be prescribed 
varenicline than NRT. Triangulating evidence across three analytical 
approaches, varenicline was more effective than NRT for smoking 
cessation in patients with mental disorders and was generally asso-
ciated with decreased or similar odds of depression or anxiety com-
pared to NRT. We report these findings cautiously as our data are 
observational and are at risk of confounding.
Supplementary Material
Supplementary data are available at Nicotine and Tobacco Research online.
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